REVENUE (Tables)

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

Summary of net revenue

The following table reflects summary revenue, net for the three and nine months ended September 30, 2020 and 2019 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Product sales, net:
CAMBIA	$	7,449	$	8,135	$	21,503	$	23,701
Zipsor	3,395		3,273		9,261		9,028
INDOCIN products(1)	13,773		—		19,207		—
SPRIX Nasal Spray(1)	5,642		—		7,244		—
Other(2)	4,007		16,094		6,468		47,160
Total product sales, net	34,266		27,502		63,683		79,889
Commercialization agreement, net	—		27,304		11,258		89,163
Royalties and milestone revenue	299		341		1,158		1,226
Total revenues	$	34,565	$	55,147	$	76,099	$	170,278

(1)Products acquired in connection with Zyla Merger represent product sales, net for the period of May 20, 2020 through September 30, 2020.

(2)Includes product sales for Gralise, which was divested in January 2020; product sales adjustments for previously divested products NUCYNTA and Lazanda; and, product sales for non-promoted products Oxaydo and SOLUMATRIX, which were acquired from Zyla in May 2020.

Summary of changes in contract assets

The following table reflects changes in the Company’s contract assets as of September 30, 2020 (in thousands):

	Balance as of			Balance as of
	December 31, 2019	Additions	Deductions	September 30, 2020
Contract asset - Collegium, net	1,896	—	(1,896)	—